ELSO (The Extracorporeal Life Support Organization)’s Post

We are glad to announce our launch of rare disease patient survey in the #US, #Germany, #Spain and the #UK, in partnership with Rare Patient Voice, to commemorate Rare Disease Day. Please stay tuned for the survey results. #rarediseaseday #raredisease #diagnosticjourney #accesstocare #diseaseawareness #socialimpact #diseaseburden #surveyresearch

We are glad to announce our launch of rare disease patient survey in the #US, #Germany, #Spain and the #UK, in partnership with Rare Patient Voice, to commemorate Rare Disease Day. Please stay tuned for the survey results. #rarediseaseday #raredisease #diagnosticjourney #accesstocare #diseaseawareness #socialimpact #diseaseburden #surveyresearch

Aug 4 2024 is the World NTM Awareness Day. Today, MicuRx joins the global community in raising awareness for non-tuberculous mycobacteria (NTM), a chronic rare lung disease with significant unmet medical needs. We are committed to work with patients, healthcare professionals, researchers to provide new treatment options for NTM. #NTM #MicuRx #MRX-5

⏳ Only a few hours remain till our final webinar! Register now if you haven't done so already: https://lnkd.in/epKv9knb⏳ The webinar will explore the skills required in implementing a step‑wise approach for patients with or at risk of developing #cardiovascular disease, recognising the risk and understanding the management of #hyperkalaemia, and discussing the latest recommendations for additional risk-based therapies in #CKD. #KidneyHealthforAll #ChronicKidneyDisease #CVD KDIGO

During Day 2 of #ADLM2024, several thought-provoking conversations took place on many subjects. Topics covered in the Roche Idea Lab sessions ranged from respiratory testing in the continuum of care to #Alzheimers disease and strategies to grow the lab. Watch this space to access the Idea Lab session on-demand in coming weeks. #diagnostics #laboratorymedicine 

Interventions for valvular disease: Highlights of #EuroPCR 2024 Chris Cook hosts Nicolas Dumonteil and Bernard Prendergast as they discuss amongst others: 🟣 record-breaking abstracts and cases, demonstrating expertise in #TAVI, #mitral, and #tricuspid procedures 🟣 LIVE cases, especially in complex TAVI scenarios, reflecting everyday practice 🟣 the crucial role of #imaging in patient selection and procedure guidance 🟣 key studies like NOTION-II and LANDMARK, and the groundbreaking ShortCut trial addressing degenerated aortic bioprostheses, and much more! https://lnkd.in/duCEPVxm

Interstitial lung disease (#ILD) is difficult to recognize, which can lead to delayed diagnosis and irreversible scarring of the lungs (#PulmonaryFibrosis).    During #ATS2024, I had the opportunity to listen to an insightful conversation about what it is like to live with ILD, featuring pulmonologist, Dr. Tanzira Zaman, and Brittany, an advocate living with scleroderma-associated ILD.     Their discussion underscored the significance of a multidisciplinary approach. Importantly, they addressed that collaborative care does not have to be formal to be impactful. It can be as simple as a phone call or personal communications between healthcare professional teams, always keeping the patient at the center.    #PatientCentricity #LifeForward #ATSCommunity

Help us spread the word about pulmonary fibrosis with your healthcare providers. Share the new CPFF Pulmonary Fibrosis Resource Library for Healthcare Professionals. This library supports healthcare professionals in understanding interstitial lung disease, causes, treatments, patient experiences, fellowship and grant opportunities, and more https://ow.ly/CtLH50RjO2m #PulmonaryFibrosis #HealthcareProfessionals

Ultrasound Assessment of the Gallbladder Wall: Study Identifies Potential Link to Cardiac Disease

As we close out Pulmonary Fibrosis Awareness Month, we would like to thank all of the organizations and individuals who worked to educate and generate awareness of this serious and often debilitating condition where there is scarring, or fibrosis, of the lungs. At aTyr, we will continue to support the pulmonary fibrosis (PF) community by working to develop efzofitimod as a potential treatment for those living with pulmonary sarcoidosis and SSc-ILD, two forms of interstitial lung disease (ILD) that can result in progressive fibrosis of the lungs. To learn more, visit www.atyrpharma.com. #PFAM #PulmonaryFibrosis #InterstitialLungDisease #PulmonarySarcoidosis #SScILD